Supplements and Featured Publications

Utilizing Antibody-Drug Conjugates and Other Novel Agents in Lung Cancer comprises articles and videos on experts discussing therapeutic strategies in the pipeline and on the market for their patients with non–small cell lung cancer.

The 2021 Year in Review: Updates in Biomarker-Driven Lung Cancer is the digital version of a print publication encompasses some of the biggest data that have read out in bimarker-driven lung cancer in 2021, along with expert insights in article and video format.

Funding From Daiichi Sankyo/Content Developed Independently by OncLive